全文获取类型
收费全文 | 93484篇 |
免费 | 6268篇 |
国内免费 | 469篇 |
专业分类
耳鼻咽喉 | 1159篇 |
儿科学 | 2576篇 |
妇产科学 | 1673篇 |
基础医学 | 11022篇 |
口腔科学 | 1969篇 |
临床医学 | 9367篇 |
内科学 | 19747篇 |
皮肤病学 | 1642篇 |
神经病学 | 8704篇 |
特种医学 | 2940篇 |
外科学 | 15039篇 |
综合类 | 1459篇 |
一般理论 | 83篇 |
预防医学 | 6655篇 |
眼科学 | 2596篇 |
药学 | 6086篇 |
4篇 | |
中国医学 | 200篇 |
肿瘤学 | 7300篇 |
出版年
2023年 | 536篇 |
2022年 | 855篇 |
2021年 | 1948篇 |
2020年 | 1191篇 |
2019年 | 1938篇 |
2018年 | 2266篇 |
2017年 | 1711篇 |
2016年 | 1939篇 |
2015年 | 2177篇 |
2014年 | 3064篇 |
2013年 | 4052篇 |
2012年 | 6430篇 |
2011年 | 6899篇 |
2010年 | 3818篇 |
2009年 | 3499篇 |
2008年 | 6049篇 |
2007年 | 6196篇 |
2006年 | 5996篇 |
2005年 | 5907篇 |
2004年 | 5655篇 |
2003年 | 5288篇 |
2002年 | 4862篇 |
2001年 | 1599篇 |
2000年 | 1434篇 |
1999年 | 1441篇 |
1998年 | 1038篇 |
1997年 | 844篇 |
1996年 | 754篇 |
1995年 | 742篇 |
1994年 | 623篇 |
1993年 | 535篇 |
1992年 | 825篇 |
1991年 | 735篇 |
1990年 | 676篇 |
1989年 | 594篇 |
1988年 | 597篇 |
1987年 | 533篇 |
1986年 | 522篇 |
1985年 | 530篇 |
1984年 | 451篇 |
1983年 | 450篇 |
1982年 | 472篇 |
1981年 | 404篇 |
1980年 | 342篇 |
1979年 | 264篇 |
1978年 | 235篇 |
1977年 | 230篇 |
1976年 | 149篇 |
1974年 | 143篇 |
1973年 | 127篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
4.
5.
6.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
7.
8.
Tien‐Yao Tsai Iat‐Lon Leong Ka‐Shun Cheng Lian‐Ru Shiao Tzu‐Hui Su Kar‐Lok Wong Paul Chan Yuk‐Man Leung 《Fundamental & clinical pharmacology》2019,33(1):52-62
A pathological feature in atherosclerosis is the dysfunction and death of vascular endothelial cells (EC). Oxidized low‐density lipoprotein (LDL), known to accumulate in the atherosclerotic arterial walls, impairs endothelium‐dependent relaxation and causes EC apoptosis. A major bioactive ingredient of the oxidized LDL is lysophosphatidylcholine (LPC), which at higher concentrations causes apoptosis and necrosis in various EC. There is hitherto no report on LPC‐induced cytotoxicity in brain EC. In this work, we found that LPC caused cytosolic Ca2+ overload, mitochondrial membrane potential decrease, p38 activation, caspase 3 activation and eventually apoptotic death in mouse cerebral bEND.3 EC. In contrast to reported reactive oxygen species (ROS) generation by LPC in other EC, LPC did not trigger ROS formation in bEND.3 cells. Pharmacological inhibition of p38 alleviated LPC‐inflicted cell death. We examined whether heparin could be cytoprotective: although it could not suppress LPC‐triggered Ca2+ signal, p38 activation and mitochondrial membrane potential drop, it did suppress LPC‐induced caspase 3 activation and alleviate LPC‐inflicted cytotoxicity. Our data suggest LPC apoptotic death mechanisms in bEND.3 might involve mitochondrial membrane potential decrease and p38 activation. Heparin is protective against LPC cytotoxicity and might intervene steps between mitochondrial membrane potential drop/p38 activation and caspase 3 activation. 相似文献
9.
10.
Conall T. Morgan Brigitte Mueller Varsha Thakur Vitor Guerra Callaghan Jull Luc Mertens Mark Friedberg Fraser Golding Mike Seed Steven E.S. Miner Edgar T. Jaeggi Cedric Manlhiot Lynne E. Nield 《The Canadian journal of cardiology》2019,35(4):453-461